Compare · CNC vs VRDN
CNC vs VRDN
Side-by-side comparison of Centene Corporation (CNC) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.26B, about 19.8x VRDN ($1.63B).
- Over the past year, CNC is up 18.2% and VRDN is down 2.1% - CNC leads by 20.3 points.
- CNC has been more active in the news (8 items in the past 4 weeks vs 4 for VRDN).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Viridian Therapeutics Inc.
- Price
- $65.33-1.28%
- $15.76-3.37%
- Market cap
- $32.26B
- $1.63B
- 1M return
- +15.94%
- -8.43%
- 1Y return
- +18.22%
- -2.08%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest CNC
- Home State Health, Centene Foundation Announce $750,000 Grant Opportunity for Missouri Organizations Improving Health Outcomes
- Long Beach Community Care Campus Expansion Advances with $10 Million Investment from Centene Foundation and Health Net
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
Latest VRDN
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- Viridian Therapeutics to Participate in Upcoming June Investor Conferences
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- Director Fairmount Funds Management Llc bought $19,999,990 worth of shares (1,176,470 units at $17.00) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.